Invesco LLC Has $306,000 Holdings in Cencora, Inc. (NYSE:COR)

Invesco LLC trimmed its holdings in Cencora, Inc. (NYSE:COR) by 36.3% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 1,100 shares of the company’s stock after selling 627 shares during the period. Invesco LLC’s holdings in Cencora were worth $306,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in COR. Howard Capital Management Inc. lifted its position in Cencora by 31.5% during the fourth quarter. Howard Capital Management Inc. now owns 1,400 shares of the company’s stock worth $315,000 after acquiring an additional 335 shares during the last quarter. Union Bancaire Privee UBP SA acquired a new stake in Cencora during the 4th quarter worth approximately $2,892,000. IFP Advisors Inc lifted its holdings in Cencora by 105.0% during the 4th quarter. IFP Advisors Inc now owns 1,810 shares of the company’s stock worth $410,000 after purchasing an additional 927 shares during the last quarter. Crestwood Advisors Group LLC boosted its stake in Cencora by 18.3% in the 4th quarter. Crestwood Advisors Group LLC now owns 1,256 shares of the company’s stock valued at $282,000 after purchasing an additional 194 shares during the period. Finally, Edge Capital Group LLC acquired a new position in Cencora in the 4th quarter valued at $2,832,000. 97.52% of the stock is currently owned by institutional investors.

Insider Activity

In other Cencora news, CEO Robert P. Mauch sold 4,969 shares of the business’s stock in a transaction on Monday, April 21st. The shares were sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the sale, the chief executive officer now owns 47,582 shares of the company’s stock, valued at approximately $13,766,900.06. The trade was a 9.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 14,579 shares of the stock in a transaction on Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total value of $4,108,507.99. Following the completion of the transaction, the chairman now owns 315,913 shares of the company’s stock, valued at $89,027,442.53. The trade was a 4.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.80% of the stock is currently owned by corporate insiders.

Cencora Stock Down 0.2%

NYSE COR opened at $293.08 on Tuesday. The business has a fifty day moving average price of $289.16 and a two-hundred day moving average price of $263.77. The stock has a market capitalization of $56.80 billion, a PE ratio of 34.00, a PEG ratio of 1.45 and a beta of 0.58. Cencora, Inc. has a fifty-two week low of $218.65 and a fifty-two week high of $309.35. The company has a debt-to-equity ratio of 6.01, a current ratio of 0.87 and a quick ratio of 0.52.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping the consensus estimate of $4.07 by $0.35. The business had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a return on equity of 344.71% and a net margin of 0.55%. Cencora’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the company earned $3.80 EPS. Equities analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were issued a $0.55 dividend. The ex-dividend date was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.75%. Cencora’s dividend payout ratio (DPR) is currently 25.52%.

Analyst Upgrades and Downgrades

COR has been the topic of several research reports. Wall Street Zen upgraded shares of Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday, March 12th. UBS Group increased their target price on shares of Cencora from $298.00 to $335.00 and gave the stock a “buy” rating in a research report on Tuesday, April 29th. Citigroup raised their target price on shares of Cencora from $330.00 to $355.00 and gave the stock a “buy” rating in a report on Thursday, May 8th. Bank of America boosted their price target on Cencora from $270.00 to $285.00 and gave the company a “neutral” rating in a research note on Friday, April 11th. Finally, Morgan Stanley set a $288.00 price objective on Cencora in a report on Tuesday, April 15th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $306.91.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.